Growth Factors as the Active Ingredient
Amniotic membrane allografts are classified as human cells, tissues, and cellular and tissue-based products (HCT/Ps) under FDA 21 CFR Part 1271. Their biological activity depends on the extracellular matrix scaffold and the growth factors retained within that scaffold during processing.1
The growth factor profile is what distinguishes an amniotic membrane allograft from a passive dressing. Where a moisture-retentive dressing maintains a healing environment, the allograft contributes signaling molecules that directly engage the stalled healing cascade. Understanding which growth factors are present, what each does, and how they interact is essential to interpreting clinical evidence across wound types.
What Growth Factors Are Present
RT-PCR and ELISA studies on preserved human amniotic membrane consistently detect mRNA and protein for eight growth factors: epidermal growth factor (EGF), transforming growth factor-alpha (TGF-α), keratinocyte growth factor (KGF), hepatocyte growth factor (HGF), basic fibroblast growth factor (bFGF / FGF-2), transforming growth factor-beta1, -beta2, and -beta3 (TGF-β1-3).2
Two additional factors are well-characterized in functional studies: vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF). VEGF is extensively documented in amniotic membrane’s pro-angiogenic activity, and PDGF contributes to fibroblast recruitment and granulation tissue formation.3,4
| Growth Factor | Primary Function in Wound Healing | Relevance by Wound Type |
|---|---|---|
| EGF | Keratinocyte migration and re-epithelialization; modulates TGF-β signaling to prevent cell cycle arrest2,5 | All wounds; critical for epithelial closure |
| FGF-2 (bFGF) | Fibroblast and endothelial cell mitogen; promotes granulation and angiogenesis2,3 | DFU, VLU, pressure injuries |
| VEGF | Endothelial cell proliferation and angiogenesis; microvessel formation3,4 | Ischemic wounds, VLU with venous hypertension |
| TGF-β | Fibroblast activation, ECM deposition, myofibroblast differentiation; dual role—required for migration at low levels, excess induces fibrosis2,5,6 | All wounds; balance matters most in surgical and hypertrophic-risk wounds |
| KGF (FGF-7) | Epithelial cell proliferation and differentiation; directs keratinocyte growth2,3 | Superficial wounds, partial-thickness burns |
| HGF | Mitogenic and motogenic for epithelial and endothelial cells; anti-fibrotic effects2,3 | VLU, pressure injury with fibrosis risk |
| PDGF | Fibroblast chemotaxis, granulation tissue formation, wound matrix remodeling4 | DFU (the target of becaplermin monotherapy) |
The epithelial layer is the primary source of EGF, KGF, HGF, and FGF-2. Amniotic membrane that has been denuded of epithelium retains these factors at significantly lower concentrations.2 Processing methods that preserve the epithelial layer therefore deliver a higher growth factor payload at the wound bed.
The Combination Effect: Why Multi-Factor Profiles Matter
Chronic wounds fail to heal because multiple signaling pathways are simultaneously disrupted. Wound fluid from non-healing ulcers is deficient in growth factors and rich in proteases that degrade what little signaling remains.7
Single-growth-factor therapy has a limited evidence base. Becaplermin (recombinant human PDGF-BB, marketed as Regranex) is the only FDA-approved recombinant growth factor for topical wound use, indicated for diabetic neuropathic ulcers. Meta-analyses report a modest absolute improvement in healing rates—approximately 10–15 percentage points over standard care alone.8 A single factor cannot compensate for the full deficit present in a chronic wound.
Amniotic membrane delivers a complementary growth factor panel simultaneously. This matters mechanistically because each phase of wound healing requires a distinct signaling profile:
- Inflammatory-to-proliferative transition: TGF-β and EGF signaling interact at the migrating keratinocyte front. Ruiz-Cañada et al. (2021) demonstrated that amniotic membrane, through EGF signaling, fine-tunes TGF-β pathway activity—reducing Smad2/3 phosphorylation and cell cycle arrest while preserving the minimal TGF-β activity required for migration.5 Too much TGF-β stalls proliferation; too little impairs migration. The combination achieves the balance.
- Angiogenesis: FGF-2 and VEGF cooperate to establish new microvasculature. Dehydrated human amnion/chorion allografts have been shown to induce angiogenesis through FGF-2 signaling in the chick chorioallantoic membrane assay.9
- Epithelialization: EGF, KGF, and HGF each contribute to keratinocyte proliferation and migration through overlapping but non-identical receptor pathways, providing redundancy that monotherapy cannot match.2,3
- ECM remodeling: TGF-β and PDGF direct fibroblast activity and collagen deposition, while HGF exerts counterbalancing anti-fibrotic effects—a regulatory loop absent in single-factor approaches.6
Processing Method and Growth Factor Retention
Growth factor retention varies by processing method. Cryopreservation at −80°C maintains native architecture and preserves high-molecular-weight hyaluronic acid complexes alongside the full growth factor panel.11 Dehydrated products, when aseptically processed without terminal irradiation, retain substantial growth factor activity—dehydrated human amnion/chorion allografts have been shown to contain measurable levels of all major growth factors and demonstrate angiogenic activity in vitro.9
Terminal sterilization via gamma irradiation degrades collagen fibers and reduces growth factor levels compared to aseptic processing.11 Lyophilization can alter basement membrane integrity and growth factor content depending on protocol parameters.12
For clinicians evaluating products, the relevant question is not broad processing category (dehydrated vs. cryopreserved) but specific manufacturing endpoints: sterilization method, epithelial layer preservation, and published growth factor characterization data. This question is discussed further in our dehydrated vs. cryopreserved decision guide.
Growth Factor Relevance by Wound Type
Different chronic wound etiologies expose different growth factor deficits, and the amniotic membrane profile maps to them differently:
| Wound Type | Primary Healing Deficit | Key Amniotic Membrane Growth Factor Contribution |
|---|---|---|
| Diabetic foot ulcer (DFU) | Impaired fibroblast function, reduced PDGF and FGF-2, stalled granulation7,8 | FGF-2 (granulation), PDGF (fibroblast chemotaxis), EGF (re-epithelialization) |
| Venous leg ulcer (VLU) | Peri-wound fibrosis, iron deposition, microvascular dysfunction, elevated proteases7 | VEGF (angiogenesis), HGF (anti-fibrotic), EGF (epithelialization), TGF-β (ECM regulation) |
| Pressure injury | Ischemia-reperfusion injury, deep tissue damage, impaired angiogenesis7 | VEGF and FGF-2 (angiogenesis), EGF and KGF (epithelial proliferation) |
| Surgical wound | Risk of dehiscence, excessive scarring, delayed closure in compromised hosts | TGF-β modulation by EGF signaling (balanced ECM regulation)5, HGF (anti-fibrotic)6 |
The Research Frontier: Growth Factor Profiling for Allograft Selection
The next phase of growth factor research is moving beyond cataloging “what’s in the membrane” to matching growth factor profiles to wound healing phase. Early work by Koizumi et al. (2001) established that the epithelial layer is the primary source of several key growth factors,2 and subsequent characterization studies have extended this to dehydrated and cryopreserved formats.9,11
Emerging research on processing extraction efficiency—biological, mechanical, and biochemical factors that shape growth factor yield—suggests that growth factor profiling could eventually guide allograft selection based on wound characteristics, healing stage, and patient-specific deficits.13 A wound in the inflammatory phase may benefit from a different growth factor panel than one ready for granulation. The ability to match growth factor profile to wound need is a logical extension of the precision medicine framework already transforming metabolic and oncologic care.
This is speculative at present. No validated clinical assay exists to guide allograft selection by growth factor profile, and no trial has compared growth-factor-matched allograft selection against standard selection. But the foundation is being laid.
Why This Foundational Content Matters
The growth factor profile is the common thread running through nearly every clinical post on this site. When we discuss amniotic membrane allografts for diabetic foot ulcers, the mechanism is growth factor engagement. When we compare dehydrated vs. cryopreserved processing, the endpoint is growth factor retention. When we explore the evidence base for venous leg ulcers, the active ingredient is the same multi-factor panel.
This post exists as reference material—the underlying science that connects every clinical topic in the library.
References
- 21 CFR Part 1271: Human cells, tissues, and cellular and tissue-based products. Code of Federal Regulations.
- Koizumi NJ, Inatomi TJ, Sotozono CJ, Fullwood NJ, Quantock AJ, Kinoshita S. Growth factor mRNA and protein in preserved human amniotic membrane. Curr Eye Res. 2001;22(1):20–27. PMID: 10694891.
- Fitriani N, Wilar G, Narsa AC, Mohammed AFA, Wathoni N. Application of amniotic membrane in skin regeneration. Pharmaceutics. 2023;15(3):748. PMC10053812.
- Parmar UPS, Surico PL, et al. Amniotic membrane transplantation for wound healing, tissue regeneration and immune modulation. Stem Cell Rev Rep. 2025;21(5):1428–1448. PMC12316762.
- Ruiz-Cañada C, Bernabé-García Á, Liarte S, Rodríguez-Valiente M, Nicolás FJ. Chronic wound healing by amniotic membrane: TGF-β and EGF signaling modulation in re-epithelialization. Front Bioeng Biotechnol. 2021;9:689328. PMC8290337.
- Signal-pubmed-ddb71c4a. TGFβ signaling instructs a conserved fibrosis-associated cell state marked by LRRC15. PubMed. PMID 42160341. 2026.
- Frykberg RG, Banks J. Challenges in the treatment of chronic wounds. Adv Wound Care. 2015;4(9):560–582. PMC4528992.
- Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. Diabetes Care. 1998;21(5):822–827.
- Koob TJ, Lim JJ, Massee M, et al. Angiogenic properties of dehydrated human amnion/chorion allografts. Int J Wound Med. 2014;1(1):33–39.
- Mohammad A, et al. Meta-analysis of amniotic membrane transplantation for chronic wound healing. Int Wound J. 2022;19(1):75–86.
- Cooke M, Tan EK, Mandrycky C, et al. Comparison of cryopreserved amniotic membrane and umbilical cord tissue with dehydrated amniotic membrane/chorion tissue. J Wound Care. 2014;23(10):465–474.
- Rodríguez-Ares MT, López-Valladares MJ, Touriño R, et al. Effects of lyophilization on human amniotic membrane. Acta Ophthalmol. 2009;87(4):396–403.
- Signal-pubmed-138bcd7a. Determinants of extraction efficiency in human amniotic membrane processing: biological, mechanical, and biochemical factors shaping growth factor yield. PubMed. PMID 42207341. 2026.
This article is intended for healthcare professionals. It provides an evidence-based overview of amniotic membrane growth factor science and does not constitute medical advice, product endorsement, or a claim of superiority over any specific competitor product. Growth factor profiling is one dimension of allograft characterization; clinical outcomes depend on multiple factors including wound characteristics, patient health status, and treatment protocol. Individual results may vary. Always consult product-specific Instructions for Use and institutional protocols.